On Oct 02, major Wall Street analysts update their ratings for $IGM Biosciences (IGMS.US)$, with price targets ranging from $9 to $25.
J.P. Morgan analyst Eric Joseph downgrades to a sell rating, and adjusts the target price from $12 to $9.
Guggenheim analyst Michael Schmidt maintains with a buy rating, and sets the target price at $20.
Stifel analyst Stephen Willey maintains with a buy rating, and maintains the target price at $25.
Wedbush analyst Robert Driscoll maintains with a buy rating, and adjusts the target price from $25 to $22.
Furthermore, according to the comprehensive report, the opinions of $IGM Biosciences (IGMS.US)$'s main analysts recently are as follows:
IGM Biosciences has announced a shift in focus towards its I&I candidates, imvotamab and IGM-2644, while discontinuing its oncology asset aplitabart following an interim review of a study for second-line metastatic renal cell carcinoma. This strategic move comes alongside significant changes in the company's executive team concurrent with the pipeline update. The recent de-prioritization of aplitabart has led to expectations of a reduced potential for significant positive catalysts for IGM in the mid-term, resulting in an assessment that the stock currently presents an unfavorable risk/reward profile.
IGM Biosciences has announced the halting of aplitabart development, choosing to concentrate solely on autoimmune indications. This strategic shift follows the full enrollment of a randomized trial that combines aplitabart with FOLFIRI and bevacizumab in second-line metastatic colorectal cancer earlier in the year. Analysts continue to endorse the potential of bispecific T cell engagers for the treatment of B cell-driven autoimmune diseases and suggest that IgM bispecifics may offer advantages in safety and efficacy over IgG-based therapies. Consequently, aplitabart has been removed from projections, and expectations are now set for imvotamab in systemic lupus erythematosus due to the redirection of resources and focus.
Following IGM Biosciences' strategic update to concentrate solely on autoimmunity, including the ceasing of aplitabart in second-line mCRC and the prioritization of imvotamab and IGM-2644 for autoimmune indications, it's acknowledged that the discontinuation of aplitabart represents a notable challenge. However, the asset was not deemed pivotal to the core investment narrative and was recognized as a high-risk program. The pipeline update is considered an appropriate course of action and is seen as an overall positive development.
The cessation of aplitabart has been met with disappointment, yet the transition of the company into a concentrated autoimmune entity specializing in T-cell engagers is likely to clarify the investment narrative, concentrate on the most promising areas, and conserve resources. It's noted that following a decline in the stock's post-market performance, a buying opportunity is perceived in anticipation of forthcoming significant autoimmune data concerning imvotamab.
Here are the latest investment ratings and price targets for $IGM Biosciences (IGMS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月2日，多家华尔街大行更新了$IGM Biosciences (IGMS.US)$的评级，目标价介于9美元至25美元。
摩根大通分析师Eric Joseph下调至卖出评级，并将目标价从12美元下调至9美元。
Guggenheim分析师Michael Schmidt维持买入评级，目标价20美元。
斯迪富分析师Stephen Willey维持买入评级，维持目标价25美元。
韦德布什分析师Robert Driscoll维持买入评级，并将目标价从25美元下调至22美元。
此外，综合报道，$IGM Biosciences (IGMS.US)$近期主要分析师观点如下：
IgM Biosciences宣布将重点转移到其I&I候选药物imvotamab和IgM-2644上，同时在对一项二线转移性肾细胞癌的研究进行中期审查后，停止了其肿瘤资产aplitabart。这一战略举措伴随着公司高管团队的重大变动，同时还进行了管道更新。最近取消了aplitabart的优先级，这导致人们对IgM在中期出现重大积极催化剂的可能性降低，因此评估认为该股票目前的风险/回报状况不佳。
IgM Biosciences宣布停止aplitabart的开发，选择只专注于自身免疫适应症。这一战略转变是在今年早些时候将阿普利塔巴特与FOLFIRI和贝伐珠单抗联合用于二线转移性结直肠癌的随机试验的全部入组之后发生的。分析人士继续支持双特异性T细胞参与剂治疗b细胞驱动的自身免疫性疾病的潜力，并认为与基于IgG的疗法相比，IgM双特异性可能在安全性和有效性方面具有优势。因此，aplitabart已从预测中删除，由于资源和重点的重定向，现已设定了对imvotamab治疗系统性红斑狼疮的预期。
继IgM Biosciences更新了仅专注于自身免疫的战略更新，包括停止在二线mCRC中使用aplitabart以及优先考虑针对自身免疫适应症的imvotamab和IgM-2644之后，人们承认停止使用aplitabart是一项重大挑战。但是，该资产不被认为对核心投资叙事至关重要，因此被视为高风险项目。管道更新被认为是适当的行动方针，被视为总体上积极的进展。
aplitabart的停止令人失望，但该公司转变为一家专门研究T细胞参与者的集中型自身免疫实体，很可能会澄清投资理念，专注于最有前途的领域，并节省资源。值得注意的是，在股票盘后表现下降之后，预计即将发布有关imvotamab的重要自身免疫数据，因此看到了买入机会。
以下为今日4位分析师对$IGM Biosciences (IGMS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
